Literature DB >> 9865824

Metastatic adenocarcinoma of unknown primary origin.

S P Hammar1.   

Abstract

Adenocarcinomas account for up to 60% of all metastatic neoplasms of unknown primary origin. In general, adenocarcinomas are the most difficult metastatic tumor to accurately identify the primary site. Some metastatic adenocarcinomas have distinctive histological features that allow for their site determination (eg, colonic adenocarcinoma, bronchioloalveolar cell carcinoma), although the majority of metastatic adenocarcinomas have histological features that are not distinctive enough to allow for a specific diagnosis of their origin. For this reason, electron microscopy and immunohistochemistry have been used to help identify the exact type (origin) of metastatic adenocarcinomas. Relatively specific ultrastructural features used to diagnose metastatic adenocarcinomas of unknown primary origin include tubular myelin, intranuclear surfactant apoprotein tubular inclusions, Clara cell granules, uniform short microvilli with filamentous cores and core rootlets, Langerhans cells associated with neoplastic cells, cytoplasmic hyaline globules, lipid droplets, glycogen, and cytoplasmic crystals. Only a few of these ultrastructural features are absolutely specific. Relatively specific immunohistochemical tests used to diagnose metastatic adenocarcinomas of unknown primary origin include prostate-specific antigen, thyroglobulin, estrogen and progesterone receptor proteins, thyroid transcription factor-I, and surfactant apoproteins. Of these, prostate-specific antigen and thyroglobulin are the most specific. The purpose of this article is to discuss the use of electron microscopy and immunohistochemistry in the site-specific diagnosis of metastatic adenocarcinomas of unknown primary origin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865824     DOI: 10.1016/s0046-8177(98)90007-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management.

Authors:  Dimitra Pantou; Haroula Tsarouha; Anna Papadopoulou; Louiza Mahaira; Ioannis Kyriazoglou; Nikiforos Apostolikas; Sophia Markidou; Theoni Trangas; Nikos Pandis; Georgia Bardi
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

2.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

3.  Immunophenotyping of Tumours.

Authors:  R Lakhtakia; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.

Authors:  Jinhai Yan; Qingzhu Wei; Wenjing Jian; Jianghuan Liu; Hongping Tang; Juan Ge; Jie Zhou; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 5.  Unknown primary tumours.

Authors:  H F Hillen
Journal:  Postgrad Med J       Date:  2000-11       Impact factor: 2.401

6.  Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update.

Authors:  Dongfeng Tan; Dani S Zander
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

7.  [Pathohistology and molecular genetic diagnostics in CUP syndrome].

Authors:  C Wittekind; L-C Horn
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

Review 8.  Molecular pathology of tumor metastasis. II. Molecular staging and differential diagnosis.

Authors:  József Tímár; Orsolya Csuka; Zsolt Orosz; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

9.  Metastatic spinal cord compression as a result of the unknown primary tumour.

Authors:  N A Quraishi; D Ramoutar; D Sureshkumar; S R Manoharan; A Spencer; G Arealis; K L Edwards; B M Boszczyk
Journal:  Eur Spine J       Date:  2014-04-02       Impact factor: 3.134

10.  Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma.

Authors:  S Kummar; M Fogarasi; A Canova; A Mota; T Ciesielski
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.